CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2021; 57(01): 08-15
DOI: 10.1055/s-0040-1718234
Review Article

Using the Immune System to Manage Immunologically-Mediated Pregnancy Loss

Sanjana Rajgopal
1   Department of Biomedical Sciences, Sri Ramachandra Institute of Higher Learning, Chennai, Tamil Nadu, India
,
Raj Raghupathy
2   Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait
› Author Affiliations

Abstract

Pregnancy is not nearly as successful as laypersons might assume, challenged as it is by several complications such as threatened abortion, spontaneous miscarriage, preeclampsia, and preterm delivery, among others. The maternal immune system has been shown to contribute to the etiopathogenesis of some of these pregnancy complications. Pro-inflammatory and anti-inflammatory cytokines have been studied for their effects on pregnancy because of their powerful and versatile effects on cells and tissues. This review addresses the relationship between pro-inflammatory cytokines and recurrent miscarriage, which is an important complication of pregnancy. References for this review were identified by using PRISMA-IPD (Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data) Guidelines by conducting searches for published articles from January 1, 1990 until March 1, 2020 in the following databases: PubMed, Google Scholar, and MEDLINE via OVID by the use of the search terms “recurrent spontaneous miscarriage,” “cytokines,” “progesterone,” “progestogen,” “dydrogesterone,” and “immunomodulation.” This review also presents the proposed mechanisms of action of pro-inflammatory cytokines in pregnancy loss, and then goes on to discuss the modulation of cytokine profiles to a state that is favorable to the success of pregnancy. In addition to its indispensable endocrinologic role of progesterone in pregnancy, it also has some intriguing immunomodulatory capabilities. We then summarize studies that show that progesterone and dydrogesterone, an orally-administered progestogen, suppress the production of pro-inflammatory cytokines and enhance the production of anti-inflammatory cytokines before mentioning clinical studies on progestogen supplementation. These studies support the contention that progestogens should be explored for the immunotherapeutic management of pregnancy complications.



Publication History

Article published online:
07 October 2020

© 2020. National Academy of Medical Sciences (India). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 
  • References

  • 1 Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfá E. Autoimmune primary ovarian insufficiency. Autoimmun Rev 2014; 13 (4-5) 427-430
  • 2 Vickram AS, Dhama K, Chakraborty S. et al. Role of antisperm antibodies in infertility, pregnancy, and potential for contraceptive and antifertility vaccine designs: research progress and pioneering vision. Vaccines (Basel) 2019; 7 (03) 116
  • 3 Stewart LA, Clarke M, Rovers M. et al. PRISMA-IPD Development Group. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 2015; 313 (16) 1657-1665
  • 4 Rink BD, Lockwood CJ. Recurrent pregnancy loss. In: Maternal-Fetal Medicine: Principles and Practice. 7th ed. Creasey RK, Resnik R, Iams JD, Lockwood CJ, Moore TR, Greene MF. eds Philadelphia, PA: Elsevier-Saunders; 2014: 108-129
  • 5 Saravelos SH, Regan L. Unexplained recurrent pregnancy loss. Obstet Gynecol Clin North Am 2014; 41 (01) 157-166
  • 6 Santos TDS, Ieque AL, de Carvalho HC. et al. Antiphospholipid syndrome and recurrent miscarriage: a systematic review and meta-analysis. J Reprod Immunol 2017; 123: 78-87
  • 7 Dinarello CA. Historical insights into cytokines. Eur J Immunol 2007; 37 (suppl 1) S34-S45
  • 8 Gulati K, Guhathakurta S, Joshi J, Rai N, Ray A. Cytokines and their role in health and disease: a brief overview. MOJ Immunol 2016; 4 (2) 00121
  • 9 Mosmann TR, Kobie JJ, Lee FE, Quataert SA. T helper cytokine patterns: defined subsets, random expression, and external modulation. Immunol Res 2009; 45 (2-3) 173-184
  • 10 Romagnani S. T cell subpopulations. Chem Immunol Allergy 2014; 100: 155-164
  • 11 Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon.. Immunol Today 1993; 14 (07) 353-356
  • 12 Raghupathy R. Pregnancy: success and failure within the Th1/Th2/Th3 paradigm. Semin Immunol 2001; 13 (04) 219-227
  • 13 Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010; 63 (06) 601-610
  • 14 Chaouat G, Menu E, Clark DA, Dy M, Minkowski M, Wegmann TG. Control of fetal survival in CBA x DBA/2 mice by lymphokine therapy. J Reprod Fertil 1990; 89 (02) 447-458
  • 15 Haimovici F, Hill JA, Anderson DJ. The effects of soluble products of activated lymphocytes and macrophages on blastocyst implantation events in vitro. Biol Reprod 1991; 44 (01) 69-75
  • 16 Pijnenborg R, Luyten C, Vercruysse L, Keith Jr JC, Van Assche FA. Cytotoxic effects of tumour necrosis factor (TNF)-α and interferon -γ on cultured human trophoblast are modulated by fibronectin. Mol Hum Reprod 2000; 6 (07) 635-641
  • 17 Kwak-Kim J, Bao S, Lee SK, Kim JW, Gilman-Sachs A. Immunological modes of pregnancy loss: inflammation, immune effectors, and stress. Am J Reprod Immunol 2014; 72 (02) 129-140
  • 18 Lee J, Choi B-C, Cho C, Hill JA, Baek K-H, Kim J-W. Trophoblast apoptosis is increased in women with evidence of TH1 immunity. Fertil Steril 2005; 83 (04) 1047-1049
  • 19 Raghupathy R, Makhseed M, Azizieh F, Omu A, Gupta M, Farhat R. Cytokine production by maternal lymphocytes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum Reprod 2000; 15 (03) 713-718
  • 20 Makhseed M, Raghupathy R, Azizieh F, Al-Azemi MM, Hassan NA, Bandar A. Mitogen-induced cytokine responses of maternal peripheral blood lymphocytes indicate a differential Th-type bias in normal pregnancy and pregnancy failure. Am J Reprod Immunol 1999; 42 (05) 273-281
  • 21 Raghupathy R, Makhseed M, Azizieh F, Hassan N, Al-Azemi M, Al-Shamali E. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell Immunol 1999; 196 (02) 122-130
  • 22 Makhseed M, Raghupathy R, Azizieh F, Omu A, Al-Shamali E, Ashkanani L. Th1 and Th2 cytokine profiles in recurrent aborters with successful pregnancy and with subsequent abortions. Hum Reprod 2001; 16 (10) 2219-2226
  • 23 Marzi M, Vigano A, Trabattoni D. et al. Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy. Clin Exp Immunol 1996; 106 (01) 127-133
  • 24 Piccinni MP, Lombardelli L, Logiodice F, Kullolli O, Romagnani S, Le Bouteiller P. T helper cell mediated-tolerance towards fetal allograft in successful pregnancy. Clin Mol Allergy 2015; 13 (01) 9
  • 25 Banerjee P, Ghosh S, Dutta M. et al. Identification of key contributory factors responsible for vascular dysfunction in idiopathic recurrent spontaneous miscarriage. PLoS One 2013; 8 (11) e80940
  • 26 Seshadri S, Sunkara SK. Natural killer cells in female infertility and recurrent miscarriage: a systematic review and meta-analysis. Hum Reprod Update 2014; 20 (03) 429-438
  • 27 Loke YW, King A. Decidual natural-killer-cell interaction with trophoblast: cytolysis or cytokine production. Biochem Soc Trans 2000; 28 (02) 196-198
  • 28 Hill JA. Maternal-embryonic cross-talk. Ann N Y Acad Sci 2001; 943: 17-25
  • 29 Moffett-King A. Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2 (09) 656-663
  • 30 Ding J, Yin T, Yan N, Cheng Y, Yang J. FasL on decidual macrophages mediates trophoblast apoptosis: a potential cause of recurrent miscarriage. Int J Mol Med 2019; 43 (06) 2376-2386
  • 31 Otun HA, Lash GE, Innes BA. et al. Effect of tumour necrosis factor-α in combination with interferon -γ on first trimester extravillous trophoblast invasion. J Reprod Immunol 2011; 88: 1-11
  • 32 Knackstedt MK, Zenclussen AC, Hertwig K. et al. Th1 cytokines and the prothrombinase fgl2 in stress-triggered and inflammatory abortion. Am J Reprod Immunol 2003; 49 (04) 210-220
  • 33 McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017; 389 (10086) 2328-2337
  • 34 Yamamoto-Furusho JK. Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways. Curr Opin Gastroenterol 2018; 34 (04) 187-193
  • 35 Stites DP, Bugbee S, Siiteri PK. Differential actions of progesterone and cortisol on lymphocyte and monocyte interaction during lymphocyte activation—relevance to immunosuppression in pregnancy. J Reprod Immunol 1983; 5 (04) 215-228
  • 36 Siiteri PK, Febres F, Clemens LE, Chang RJ, Gondos B, Stites D. Progesterone and maintenance of pregnancy: is progesterone nature’s immunosuppressant.. Ann N Y Acad Sci 1977; 286: 384-397
  • 37 Shah NM, Imami N, Johnson MR. Progesterone modulation of pregnancy-related immune responses. Front Immunol 2018; 9: 1293
  • 38 Kincl FA, Ciaccio LA. Suppression of immune responses by progesterone. Endocrinol Exp 1980; 14 (01) 27-33
  • 39 Choi BC, Polgar K, Xiao L, Hill JA. Progesterone inhibits in-vitro embryotoxic Th1 cytokine production to trophoblast in women with recurrent pregnancy loss. Hum Reprod 2000; 15 (suppl 1) 46-59
  • 40 Schindler AE. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium. Maturitas 2009; 65 (suppl 1) S3-S11
  • 41 Raghupathy R, Al E Mutawa, Makhseed M, Azizieh F, Szekeres-Bartho J. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. BJOG 2005; 112 (08) 1096-1101
  • 42 Xu WM, Xiao ZN, Wang XB, Huang Y. IL-17 induces fetal loss in a CBA/J×BALB/c mouse model, and an anti-IL-17 antibody prevents fetal loss in a CBA/J × DBA/2 mouse model. Am J Reprod Immunol 2016; 75 (01) 51-58
  • 43 Wang W-J, Hao C-F. Yi-Lin. et al. Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients. J Reprod Immunol 2010; 84 (02) 164-170
  • 44 Wu L, Luo LH, Zhang Y-X. et al. Alteration of Th17 and Treg cells in patients with unexplained recurrent spontaneous abortion before and after lymphocyte immunization therapy. Reprod Biol Endocrinol 2014; 12 (74) 74
  • 45 AbdulHussain G, Azizieh F, Makhseed M. et al. Effects of progesterone, dydrogesterone and estrogen on the production of Th1/Th2/Th17 cytokines by lymphocytes from women with recurrent spontaneous miscarriage. J Reprod Immunol 2020; 140: 103132
  • 46 Raghupathy R, Al-Azemi M. Modulation of cytokine production by the dydrogesterone metabolite dihydrodydrogesterone. Am J Reprod Immunol 2015; 74 (05) 419-426
  • 47 Verma P, Verma R, Nair RR. et al. Altered crosstalk of estradiol and progesterone with myeloid-derived suppressor cells and Th1/Th2 cytokines in early miscarriage is associated with early breakdown of maternal-fetal tolerance. Am J Reprod Immunol 2019; 81 (02) e13081
  • 48 Szekeres-Bartho J, Kilar F, Falkay G, Csernus V, Torok A, Pacsa AS. Progesterone-treated lymphocytes of healthy pregnant women release a factor inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol 1985; 9: 15-18
  • 49 Szekeres-Bartho J, Polgar B. PIBF: the double edged sword. Pregnancy and tumor. Am J Reprod Immunol 2010; 64 (02) 77-86
  • 50 Arck P, Hansen PJ, Mulac Jericevic B, Piccinni MP, Szekeres-Bartho J. Progesterone in pregnancy: endocrine-immune cross talk in mammalian species and the role of stress. Am J Reprod Immunol 2007; 58: 268-279
  • 51 Polgár B, Nagy E, Mikó E, Varga P, Szekeres-Barthó J. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 2004; 71 (05) 1699-1705
  • 52 Check JH, Levin E, Bollendorf A, Locuniak J. Miscarriage in the first trimester according to the presence or absence of the progesterone-induced blocking factor at three to five weeks from conception in progesterone supplemented women. Clin Exp Obstet Gynecol 2005; 32 (01) 13-14
  • 53 Kalinka J, Szekeres-Bartho J. The impact of dydrogesterone supplementation on hormonal profile and progesterone-induced blocking factor concentrations in women with threatened abortion. Am J Reprod Immunol 2005; 53 (04) 166-171
  • 54 Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J. Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery. J Reprod Immunol 2009; 80 (1-2) 91-99
  • 55 Haas DM, Ramsey PS. Progestogen for preventing miscarriage. Cochrane Database Syst Rev 2013; (10) CD003511
  • 56 Wahabi HA, Fayed AA, Esmaeil SA, Bahkali KH. Progestogen for treating threatened miscarriage. Cochrane Database Syst Rev 2018; 8: CD005943
  • 57 Szekeres-Bartho J, Balasch J. Progestagen therapy for recurrent miscarriage. Hum Reprod Update 2008; 14 (01) 27-35
  • 58 Ismail AM, Abbas AM, Ali MK, Amin AF. Peri-conceptional progesterone treatment in women with unexplained recurrent miscarriage: a randomized double-blind placebo-controlled trial. J Matern Fetal Neonatal Med 2018; 31 (03) 388-394
  • 59 Czyzyk A, Podfigurna A, Genazzani AR, Meczekalski B. The role of progesterone therapy in early pregnancy: from physiological role to therapeutic utility. Gynecol Endocrinol 2017; 33 (06) 421-424
  • 60 Stanczyk FZ. Pharmacokinetics of progesterone administered by the oral and parenteral routes. J Reprod Med 1999; 44 (suppl 2) 141-147
  • 61 Simon JA, Robinson DE, Andrews MC. et al. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril 1993; 60 (01) 26-33
  • 62 Maxson WS, Hargrove JT. Bioavailability of oral micronized progesterone. Fertil Steril 1985; 44 (05) 622-626
  • 63 Mirza FG, Patki A, Pexman-Fieth C. Dydrogesterone use in early pregnancy. Gynecol Endocrinol 2016; 32 (02) 97-106
  • 64 El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol 2005; 97 (05) 431-434
  • 65 Kumar A, Begum N, Prasad S, Aggarwal S, Sharma S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil Steril 2014; 102 (05) 1357-1363.e3
  • 66 Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015; 31 (06) 422-430
  • 67 Makhseed M, Raghupathy R, El-Shazly S, Azizieh F, Al-Harmi JA, Al-Azemi MM. Pro-inflammatory maternal cytokine profile in preterm delivery. Am J Reprod Immunol 2003; 49 (05) 308-318
  • 68 Sykes L, MacIntyre DA, Yap XJ, Teoh TG, Bennett PR. The Th1:th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm 2012; 2012: 967629
  • 69 Pandey M, Chauhan M, Awasthi S. Interplay of cytokines in preterm birth. Indian J Med Res 2017; 146 (03) 316-327
  • 70 Raghupathy R. Cytokines as key players in the pathophysiology of preeclampsia. Med Princ Pract 2013; 22 (Suppl. 01) 8-19
  • 71 Raghupathy R, Al E Mutawa, Makhseed M, Al-Azemi M, Azizieh F. Redirection of cytokine production by lymphocytes from women with pre-term delivery by dydrogesterone. Am J Reprod Immunol 2007; 58 (01) 31-38
  • 72 Hudic I, Schindler AE, Szekeres-Bartho J, Stray-Pedersen B. Dydrogesterone and pre-term birth. Horm Mol Biol Clin Investig 2016; 27 (03) 81-83
  • 73 Tskhay V, Schindler A, Shestakova M, Klimova O, Narkevich A. The role of progestogen supplementation (dydrogesterone) in the prevention of preeclampsia. Gynecol Endocrinol 2019; 26: 1-4